Lordestin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lordestin

Property Description
Active ingredient Desloratadine
Form Tablet, Oral Solution, Syrup
Pharmacological class Second-generation H₁-receptor antagonist
Common use Anti-allergic agent
Origin Synthetic (Active metabolite)

Lordestin is the trade name for the active substance Desloratadine, a pharmaceutical entity classified as a second-generation H₁-receptor antagonist, commonly identified as a non-sedating antihistamine. This synthetic compound is the principal active metabolite of the older antihistamine Loratadine, having been isolated to maximize therapeutic effectiveness and limit unwanted side effects. Its status as a second-generation agent is characterized by high peripheral selectivity. This means it primarily targets receptors outside the central nervous system, helping to reduce allergic symptoms without causing the significant drowsiness associated with first-generation agents.


Composition, Forms, and Origin

Lordestin is formulated as a single-ingredient product and is available for oral (systemic) administration in several distinct dosage forms to suit patient requirements, including the film-coated tablet, oral solution, and syrup. The formulation, which often utilizes a sweetened aqueous vehicle for the liquid forms, supports ease of use for both adults and certain pediatric groups. The general purpose of this medication is to function as an anti-allergic agent. By effectively blocking the H₁ receptors where the body’s natural inflammatory chemical, histamine, attaches, the medicine generally helps to relieve the physical manifestations of histamine-mediated symptoms, such as the persistent itching or the runny nose experienced during a typical seasonal allergic reaction.

Regulatory References

  1. NIH: Desloratadine Information

What side effects are possible with Lordestin?

Possible Side Effects and Safety Information

Lordestin (desloratadine) is generally well tolerated, with the safety profile established through clinical trials and post-marketing surveillance.

Adverse Reactions

Frequency Classification System-Organ Class Involved (Examples) Adverse Reactions
Common (Reported in excess of placebo) General Disorders, Nervous System, GI Fatigue, Dry mouth, Headache
Very Rare Immune System, Cardiac, Hepatobiliary, CNS Hypersensitivity reactions (anaphylaxis, angioedema, rash, dyspnea), Tachycardia, Palpitations, Hepatitis, Convulsions, Hallucinations, Insomnia
Not Known (Frequency cannot be estimated) Metabolism, Cardiac, Psychiatric Increased appetite, Weight increase, QT prolongation, Arrhythmia, Abnormal behavior, Aggression

Serious and Clinically Significant Safety Information

Serious Reactions: Documented serious adverse reactions include hypersensitivity reactions (e.g., anaphylaxis and angioedema), seizures (convulsions), and hepatitis/jaundice.

Population-Specific Considerations:

  • Hepatic or Renal Impairment: Caution is recommended in patients with severe liver or kidney problems due to altered drug elimination.
  • Seizures: Use with caution in patients with a personal or family history of seizures, as young children may be particularly susceptible.
  • Pregnancy and Breast-feeding: Use is generally not recommended during pregnancy or breast-feeding unless specifically advised by a healthcare provider, due to limited established safety data in these groups.

Restrictions and Limitations:

  • Contraindication: Lordestin is contraindicated in patients with known hypersensitivity to desloratadine, any component of the formulation, or loratadine.
  • Mental Alertness: Patients should be advised to assess their individual response to the medication before engaging in activities requiring full mental alertness, such as driving or operating machinery, although clinical trials suggest no or negligible influence for most individuals.

Overdose and Emergency Response

Overdose Manifestations and Risks

The official regulatory documentation states that the adverse event profile associated with Lordestin overdose is generally similar to that seen with therapeutic doses, but the magnitude of the effects can be higher. Although clinical trials using up to nine times the normal dose showed no clinically relevant effects, there is documented concern regarding the cardiovascular system. Specific serious outcomes noted in regulatory reports include tachycardia (fast heart rate) and the potential for QT prolongation, which affects the heart's electrical rhythm. Central nervous system effects such as drowsiness, headache, and agitation are also noted in overdose scenarios, confirming that the physiological systems affected include both the CNS and the cardiovascular system.


Required Emergency Actions and Management

If an overdose is suspected, immediate medical attention must be sought right away, or emergency services should be contacted, especially if severe symptoms like seizures, trouble breathing, or collapse occur. This urgent action is required because no specific antidote is known for Desloratadine. Management focuses on symptomatic and supportive treatment, along with considering standard measures to remove unabsorbed active substance. It is also officially noted that Desloratadine is not eliminated by haemodialysis. A specific regulatory note highlights that for the paediatric population, the magnitude of overdose effects can be higher than in adults.

Therapeutic Uses of Lordestin

Main Therapeutic Uses of Lordestin

Lordestin is a non-sedating antihistamine medication used primarily to manage the symptoms of allergic reactions. Its active ingredient, desloratadine, works by blocking the action of histamine, a natural substance in the body that triggers allergic symptoms when the immune system reacts to external irritants.

Allergic Rhinitis

Lordestin is indicated for the relief of symptoms associated with allergic rhinitis, which includes both seasonal allergies and year-round (perennial) allergies. It addresses the following symptoms:

  • Nasal symptoms: Sneezing, runny nose, and nasal itching.
  • Ocular symptoms: Itchy, red, or watery eyes.
  • Throat symptoms: Itching of the palate or throat.

By managing these symptoms, the medication helps improve daily functioning and sleep quality for individuals affected by respiratory allergies.

Chronic Idiopathic Urticaria

In addition to respiratory allergies, Lordestin is used to treat chronic idiopathic urticaria, a condition characterized by the regular appearance of hives (urticaria) without an identifiable external cause. The benefits in this context include:

  • Reduction of itching: Decreasing the intensity of the pruritus associated with hives.
  • Reduction of skin lesions: Minimizing the size and number of hives on the skin.

Mechanism and Benefits

As a long-acting antihistamine, Lordestin provides several specific clinical benefits:

  • Non-sedating profile: It is designed to relieve symptoms without causing drowsiness, allowing individuals to maintain their usual level of alertness during daily activities.
  • Duration of effect: The medication is formulated to provide symptom relief for a full 24-hour period after a single application.
  • Broad efficacy: It is effective against both indoor allergens, such as dust mites and pet dander, and outdoor allergens, such as pollen and molds.

Eligibility and Restrictions for Use

Lordestin (desloratadine) is an antihistamine primarily indicated for the relief of symptoms associated with allergic rhinitis (such as hay fever) and chronic idiopathic urticaria (hives). It is available in various formulations and is generally approved for use in adults and children over certain ages, depending on the specific product (e.g., typically 6 or 12 years and older for tablets, and as young as 6 months for oral solution for some indications).


Contraindications (Who Should Not Use Lordestin)

  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to desloratadine, any of the product's ingredients, or to loratadine (a related antihistamine) should not use this medication.

Precautions (Use with Caution)

Certain patient groups require caution and may need a dosage adjustment or closer monitoring by a healthcare provider:

  • Kidney or Liver Impairment: Patients with severe kidney or liver disease may have higher levels of the medication in their system, which could require an adjustment to the dosing schedule.
  • Seizure History: Caution is advised for patients with a medical or family history of seizures, particularly in young children, as seizures have been reported rarely.
  • Pregnancy and Breastfeeding: While studies suggest a low risk, the medication should only be used during pregnancy or breastfeeding if the potential benefit justifies the risk, as desloratadine passes into breast milk.

What should I know about interactions with other medicines?

Lordestin (desloratadine) has a generally low risk for clinically significant interactions with many commonly co-administered medicines.

Documented Interactions

Clinical trials have evaluated the co-administration of desloratadine with certain medicinal products. No clinically relevant interactions were observed when desloratadine tablets were administered alongside erythromycin (an antibiotic) or ketoconazole (an antifungal agent).

While desloratadine did not potentiate the performance-impairing effects of alcohol in a clinical pharmacology trial, regulatory caution is still recommended. This is based on post-marketing reports that have documented cases of alcohol intolerance and intoxication associated with concomitant use.

Interaction Notes

Condition Interaction-Related Note
Severe Renal Insufficiency Use with caution due to the potential for slower clearance of the active substance.
Paediatric Population Formal interaction studies have only been conducted in adults.

Overall, the regulatory profile suggests that Lordestin's primary interaction-related consideration is the cautious use with alcohol, while established drug-drug studies with erythromycin and ketoconazole showed no significant effect.

Mechanism of Action

The mechanism of Desloratadine (Lordestin) is defined by its selective action on the body's histamine signaling system, achieved through two main mechanistic domains that influence core regulatory pathways.

Targeting the Histamine H1 -Receptor (Inverse Agonism)

This domain covers the core molecular interaction: the drug acts as an inverse agonist at the peripheral Histamine H1 -receptor ( H1 R). By stabilizing the receptor in an inactive state, the drug initiates or suppresses signaling sequences that modify early molecular steps, thereby modulating the physiological processes initiated by histamine, including sensory nerve excitation and increased vascular permeability.

System Selectivity and Inflammatory Modulation

This domain addresses the drug's distribution and its secondary anti-inflammatory capabilities. The molecule's chemical properties enforce system selectivity, confining its H1 R blockade to the periphery, which maintains minimal engagement of central nervous system (CNS) H1 R activity. Furthermore, the drug engages mechanisms that modulate the release of secondary inflammatory mediators from mast cells, and influences the downstream signaling of prolonged pathway activation.

Dosage and Administration Information

Official Administration Guidelines

Lordestin (desloratadine) is administered orally once daily. The specific dosage and method of use are established for different age groups and patient populations. The medicine can be taken regardless of food intake.

Dosing by Age Group

Age Group Recommended Oral Dose Frequency
Adults & Adolescents (12 years and older) 5 mg Once Daily
Children 6 to 11 years 2.5 mg Once Daily
Children 12 months to 5 years 1.25 mg Once Daily
Children 6 to 11 months 1 mg Once Daily

For adult patients with severe kidney or liver impairment, a starting dose of one 5 mg tablet every other day is utilized.

Preparation and Administration Specifics

  • Film-Coated Tablets: Tablets are swallowed whole with water.
  • Oral Solution: The dose is measured using a calibrated oral syringe or measuring dropper. A household spoon is not used for measurement.
  • Orally Disintegrating Tablets (ODT): Dry hands are used to peel back the foil packaging. The tablet is placed on the tongue to dissolve and then swallowed with saliva. Water is not required for administration.

If a dose is missed, the missed dose is taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped to avoid taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key research findings and clinical data related to Lordestin's (desloratadine) properties, use, and characteristics in established clinical settings.


Study Summary for Allergic Conditions

Research has primarily investigated the compound in individuals experiencing allergic rhinitis (e.g., hay fever) and chronic idiopathic urticaria (hives). Key clinical trials were reviewed, focusing on symptom relief over 24-hour periods.

  • In randomized controlled trials (RCTs), trials reported differences in measures related to patient comfort (e.g., reduced sneezing, itching, and rash) compared to placebo.
  • Researchers investigated the compound's interaction with neurotransmitter pathways in the central nervous system, reflecting its selective activity as a peripheral H1-receptor antagonist.
  • Pooled analyses of major studies reported data reflecting symptom scores (e.g., total nasal symptom scores) over treatment periods, supporting a sustained effect.

Pharmacokinetics and Safety Profile

Further research has focused on the compound's absorption, distribution, metabolism, and excretion (ADME) profile, as well as its safety characteristics.

  • Maximum plasma concentration (C max) was consistently reached after approximately three hours following oral administration, consistent with the timeline for absorption kinetics.
  • The safety data was primarily drawn from the adverse event (AE) reporting in the clinical trials. The most commonly reported adverse events included headache, dry mouth, and fatigue, with incidence rates generally similar to placebo.
  • Studies examining use in individuals with severe liver issues are limited, and research regarding the use of the compound in this population is ongoing.

Comparative Studies

Research compared the compound to older treatments (e.g., other second-generation antihistamines).

  • These head-to-head trials primarily assessed differences in study endpoints (e.g., responder rates, total relief metrics) and specific adverse event profiles, often finding similar overall efficacy and safety profiles among the second-generation class.
  • Results from these comparative studies are used to understand the compound's profile relative to existing therapies.

Frequently Asked Questions (FAQ)

Common questions about Lordestin (FAQ)


Q: What age groups is Lordestin approved for?

A: The medicine is approved for the relief of symptoms in adults and adolescents 12 years and older. The official product information also shows that it is approved for younger pediatric patients in appropriate liquid dosage forms, sometimes starting as early as 6 months of age, depending on the specific product and indication.


Q: How quickly should I expect Lordestin to start working?

A: Studies focusing on how the drug is absorbed show that the maximum concentration of the active substance in the body is generally reached about three hours after taking the medicine. This pharmacokinetic measurement provides an indication of the absorption timeline.


Q: How long does Lordestin stay in your system?

A: Pharmacokinetic studies report a measure called the elimination half-life for the active substance, which is approximately 27 hours. The half-life describes the time required for half of the substance to be naturally cleared from the system.


Q: Can Lordestin cause weight gain or weight loss?

A: The official safety information includes weight increase among the adverse reactions reported after the drug was marketed. However, this is noted as a rare event with an unknown frequency. Weight loss is not specifically noted in the regulatory adverse reaction information.


Q: What are the reported psychological side effects of Lordestin?

A: Adverse events related to the central nervous system or psychiatric effects have been reported during post-marketing surveillance. These reports include rare occurrences of hallucinations and insomnia, as well as other events like abnormal behavior and aggression where the frequency is not known.


Q: Is Lordestin known to cause any long-term effects on the heart?

A: Official safety reviews have assessed the potential risk of an abnormal heart rhythm called QT interval prolongation. Based on the available data, a clear, established link between the use of desloratadine and this condition was not established during the review.


Q: Are there any specific safety warnings for older adults using Lordestin?

A: Official precautions indicate that considerations for the elderly population include factors such as possible changes in organ function, including decreased liver, kidney, or heart function. This is noted due to a potential for an increased risk of adverse reactions in this population.


Q: What if I experience a rare or serious side effect from Lordestin?

A: Official labeling indicates that for documented serious reactions like hypersensitivity or anaphylaxis (severe allergic reactions), immediate discontinuation of the medicine and a review of alternative treatments are mentioned as regulatory guidance.


Q: Does Lordestin carry a Black Box Warning from the FDA?

A: The official prescribing information released by the U.S. Food and Drug Administration (FDA) for this medicine does not include a Boxed Warning (often referred to as a Black Box Warning). This warning is the FDA's strongest safety measure for serious risks.


Q: Is Lordestin considered a controlled substance?

A: No, the medicine is not classified as a controlled substance by U.S. regulatory authorities. This classification is typically reserved for drugs that carry a potential for dependence or abuse.


Q: Is there a risk of dependence or addiction with Lordestin?

A: The medicine is not classified as a controlled substance by US regulatory authorities. Furthermore, the official product warnings do not include risks related to dependence or addiction.


Q: Is Lordestin used to treat anxiety or sleep issues off-label?

A: The official indications for this medicine are limited to the relief of symptoms associated with allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). Official documents do not list anxiety or general sleep issues as approved uses.


Q: Do I need a prescription from a doctor to get Lordestin?

A: The product's prescription status can vary depending on the country, the dose, and the specific formulation. In some regions, the medicine is available over-the-counter (OTC).


Q: Are there generic versions of Lordestin available?

A: Official regulatory records confirm that both the brand-name product, Lordestin, and generic versions containing the active ingredient desloratadine are available in the market. Generic versions contain the same active ingredient.


Q: What is the list of ingredients in Lordestin tablets/capsules?

A: Official labeling describes the medicine as containing the active ingredient, desloratadine. Like all medications, it also contains various inactive ingredients (or excipients) that are necessary for the tablet or solution formulation. The complete list of these inactive substances is detailed in the official product information document.


Q: Can Lordestin interact with herbal supplements like St. John's Wort?

A: There is limited official information provided regarding specific interactions with most herbal remedies or supplements. The regulatory approach suggests a cautious consideration of supplements that may cause side effects similar to the drug, such as sleepiness or dry mouth.


Q: Has Lordestin been recalled for any safety issues?

A: Official regulatory channels have documented the recall of specific batches of generic desloratadine tablets in the past. These recalls were generally due to the presence of an impurity exceeding acceptable limits.


Q: Are there specific laboratory tests recommended while taking Lordestin?

A: Data from clinical trials indicated that the frequency of general laboratory abnormalities was similar between patients taking the medicine and those taking a placebo (an inactive substance).

How should Lordestin be stored and disposed of?

How to Store and Dispose of Lordestin?

Lordestin (desloratadine) must be stored strictly according to official regulatory specifications to maintain its stability and effectiveness.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature (20°C to 25°C or 68°F to 77°F).
Protection Protect tablets from excessive moisture; do not freeze the oral solution or syrup.
Container Keep the medicine in its original container and ensure it is tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should be disposed of via a medicine take-back program if one is available locally. If a program is not accessible, the product may be mixed with an undesirable substance, placed in a sealed bag, and discarded in household trash. Do not flush Lordestin down a toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lordestin found in:

A-Z Index: